Spevigo (also known by its generic name spesolimab-sbzo) was approved in 2022 for the treatment of adults with generalized pustular psoriasis (GPP) flares. In 2024, Spevigo was approved for the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg.
In adults experiencing GPP flares, Spevigo is administered once by intravenous (IV) infusion. If flare symptoms persist, a second dose may be administered one week after the initial dose.
In adults and pediatric patients aged 12 and above weighing ≥40 kg not experiencing a GPP flare, Spevigo is given by injection under the skin. The initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterward.
To learn more, please visit the Spevigo website.
